
Roongroj Bhidayasiri, Frcp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5698515/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Access and Attitudes Toward Palliative Care Among Movement Disorders Clinicians. Movement Disorders, 2022, 37, 182-189.	2.2	18
2	Neuroimaging Pearls from the <scp>MDS</scp> Congress Video Challenge. Part 2: Acquired Disorders. Movement Disorders Clinical Practice, 2022, 9, 311-325.	0.8	2
3	Doctor Hope; Calming and Comforting Loneliness in Parkinson's Disease. Clinical Parkinsonism & Related Disorders, 2022, 6, 100131.	0.5	0
4	A South East Asian perspective of neuropsychiatric startle syndromes of latah. Parkinsonism and Related Disorders, 2022, 95, 138-142.	1.1	3
5	We Move or Are We Moved? Unpicking the Origins of Voluntary Movements to Better Understand Semivoluntary Movements. Frontiers in Neurology, 2022, 13, 834217.	1.1	1
6	Parkinson's disease severity clustering based on tapping activity on mobile device. Scientific Reports, 2022, 12, 3142.	1.6	13
7	Umami and Other Taste Perceptions in Patients With Parkinson's Disease. Journal of Movement Disorders, 2022, 15, 115-123.	0.7	4
8	Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale. Journal of Movement Disorders, 2022, 15, 151-155.	0.7	4
9	Improving functional disability in patients with tremor: A clinical perspective of the efficacies, considerations, and challenges of assistive technology. Journal of the Neurological Sciences, 2022, 435, 120197.	0.3	10
10	Task Force Consensus on Nosology and Cutâ€Off Values for Axial Postural Abnormalities in Parkinsonism. Movement Disorders Clinical Practice, 2022, 9, 594-603.	0.8	15
11	Six Action Steps to Address Global Disparities in Parkinson Disease. JAMA Neurology, 2022, 79, 929.	4.5	39
12	Using machine learning-based analytics of daily activities to identify modifiable risk factors for falling in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 82, 77-83.	1.1	3
13	Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures. Movement Disorders, 2021, 36, 76-82.	2.2	31
14	Urinary dysfunction in Parkinson's disease. International Review of Movement Disorders, 2021, , 209-249.	0.1	0
15	Challenges of Parkinson's Disease Care in Southeast Asia. , 2021, , 1-21.		4
16	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission, 2021, 128, 321-335.	1.4	37
17	Editorial: Inclusion, equity, diversity and social justice in movement disorders research. Parkinsonism and Related Disorders, 2021, 85, 114-116.	1.1	3
18	Will Artificial Intelligence Outperform the Clinical Neurologist in the Near Future? Yes. Movement Disorders Clinical Practice, 2021, 8, 525-528.	0.8	4

#	Article	IF	CITATIONS
19	Parkinson's Disease and <scp>Post–COVID</scp> â€19 Syndrome: The Parkinson's <scp>Longâ€COVID</scp> Spectrum. Movement Disorders, 2021, 36, 1287-1289.	2.2	51
20	Peak-Dose Ballism Associated with Declining Implantable Pulse Generator Battery Life in Deep Brain Stimulation for Parkinson's Disease. Journal of Movement Disorders, 2021, 14, 166-169.	0.7	0
21	The impact of COVID-19 on palliative care for people with Parkinson's and response to future pandemics. Expert Review of Neurotherapeutics, 2021, 21, 615-623.	1.4	15
22	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. Scientific Reports, 2021, 11, 9611.	1.6	21
23	Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns. Parkinsonism and Related Disorders, 2021, 87, 39-40.	1.1	1
24	Monoamine Levels and Parkinson's Disease Progression: Evidence From a High-Performance Liquid Chromatography Study. Frontiers in Neuroscience, 2021, 15, 605887.	1.4	11
25	Objective vowel sound characteristics and their relationship with motor dysfunction in Asian Parkinson's disease patients. Journal of the Neurological Sciences, 2021, 426, 117487.	0.3	6
26	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. Parkinsonism and Related Disorders, 2021, 89, 186-194.	1.1	26
27	Impact of <scp>COVIDâ€19</scp> on Patient Care, Training, and Research in Movement Disorders in <scp>MDSâ€AOS</scp> Region. Movement Disorders, 2021, 36, 2457-2458.	2.2	3
28	Early Factors for Predicting Discontinuation to Subcutaneous Apomorphine Infusion in Parkinson's disease: A Prospective Analysis of the Thai Apomorphine Registry. Parkinsonism and Related Disorders, 2021, 91, 146-151.	1.1	6
29	Using Machine Learning for Predicting the Best Outcomes With Electrical Muscle Stimulation for Tremors in Parkinson's Disease. Frontiers in Aging Neuroscience, 2021, 13, 727654.	1.7	8
30	Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?. PLoS ONE, 2021, 16, e0261302.	1.1	7
31	Botulinum Neurotoxin-A Injection in Adult Cervical Dystonia and Spastic Paresis: Results From the INPUT (INjection Practice, Usage and Training) Survey. Frontiers in Neurology, 2020, 11, 570671.	1.1	4
32	Digital phenotyping in Parkinson's disease: Empowering neurologists for measurement-based care. Parkinsonism and Related Disorders, 2020, 80, 35-40.	1.1	18
33	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism and Related Disorders, 2020, 77, 141-145.	1.1	4
34	Orofacial dystonia and asssociated bulbar symptoms in multiple system atrophy: A blinded video analysis. Journal of the Neurological Sciences, 2020, 417, 116992.	0.3	6
35	Addressing knowledge gaps in Parkinson's disease: a report on the Movement Disorder Society's Centre-to-Centre initiative to improve Parkinson's disease services in Lao People's Democratic Republic. BMC Medical Education, 2020, 20, 239.	1.0	4
36	<p>lf Your Patients Were Too Embarrassed to Go Out in Public, What Would You Do? – Public Education to Break the Stigma on Parkinson's Disease Using Integrated Media</p> . Patient Related Outcome Measures, 2020, Volume 11, 143-148.	0.7	10

#	Article	IF	CITATIONS
37	Prescription of Anticholinergics in Tardive Syndromes: A "Dual Center―Survey among Psychiatrists. Parkinson's Disease, 2020, 2020, 1-4.	0.6	0
38	Mastering nocturnal jigsaws in Parkinson's disease: a dusk-to-dawn review of night-time symptoms. Journal of Neural Transmission, 2020, 127, 763-777.	1.4	5
39	Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. Parkinsonism and Related Disorders, 2020, 72, 82-87.	1.1	25
40	Impaired ability to turn in bed in parkinson's disease as a potential rare cause of positional asphyxia: a sensor-based analysis. Clinical Neurology and Neurosurgery, 2020, 192, 105713.	0.6	5
41	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries. Expert Review of Neurotherapeutics, 2020, 20, 523-537.	1.4	7
42	Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management. PLoS ONE, 2020, 15, e0243051.	1.1	8
43	COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson's Disease Patient Care. Journal of Movement Disorders, 2020, 13, 105-114.	0.7	70
44	Assistive technologies in Parkinson's disease. , 2020, , 713-729.		1
45	Title is missing!. , 2020, 15, e0243051.		0
46	Title is missing!. , 2020, 15, e0243051.		0
47	Title is missing!. , 2020, 15, e0243051.		0
48	Title is missing!. , 2020, 15, e0243051.		0
49	Title is missing!. , 2020, 15, e0243051.		0
50	Title is missing!. , 2020, 15, e0243051.		0
51	How to spot ocular abnormalities in progressive supranuclear palsy? A practical review. Translational Neurodegeneration, 2019, 8, 20.	3.6	17
52	Subthalamic deep brain stimulation aggravates speech problems in Parkinson's disease: Objective and subjective and subjective analysis of the influence of stimulation frequency and electrode contact location. Parkinsonism and Related Disorders, 2019, 66, 110-116.	1.1	8
53	Posturographic abnormalities in ambulatory atypical parkinsonian disorders: Differentiating characteristics. Parkinsonism and Related Disorders, 2019, 66, 94-99.	1.1	11
54	Objective Monitoring of Driving Behavior in Parkinson's Disease: The Utility of the Chula Parkinson Car®. European Neurology, 2019, 81, 128-138.	0.6	0

#	Article	IF	CITATIONS
55	Management of Spastic Paresis and Cervical Dystonia: Access to Therapeutic Innovations Through an International Program of Practical Courses. Clinical Therapeutics, 2019, 41, 2321-2330.e4.	1.1	5
56	More than hemifacial spasm? A case of unilateral facial spasms with systematic review of red flags. Journal of the Neurological Sciences, 2019, 407, 116532.	0.3	3
57	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Movement Disorders, 2019, 34, 791-798.	2.2	49
58	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	4.9	116
59	Long-term Apomorphine Infusion Users Versus Short-term Users: An International Dual-center Analysis of the Reasons for Discontinuing Therapy. Clinical Neuropharmacology, 2019, 42, 172-178.	0.2	12
60	Exploring bedside clinical features of parkinsonism: A focus on differential diagnosis. Parkinsonism and Related Disorders, 2019, 59, 74-81.	1.1	8
61	Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders. Parkinsonism and Related Disorders, 2019, 59, 82-92.	1.1	22
62	Evaluation of nocturnal hypokinesia in Parkinson's disease using a novel patient/proxy questionnaire and correlations with objective monitoring. Parkinsonism and Related Disorders, 2019, 61, 219-223.	1.1	10
63	Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. Journal of the Neurological Sciences, 2018, 389, 67-75.	0.3	88
64	Can therapeutic Thai massage improve upper limb muscle strength in Parkinson's disease? An objective randomized-controlled trial. Journal of Traditional and Complementary Medicine, 2018, 8, 261-266.	1.5	13
65	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 2018, 265, 856-862.	1.8	51
66	Symptomatic orthostatic hypotension in Parkinson's disease patients: Prevalence, associated factors and its impact on balance confidence. Journal of the Neurological Sciences, 2018, 385, 168-174.	0.3	12
67	Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 10-18.	1.1	37
68	Effects of Transcranial Direct Current Stimulation Plus Physical Therapy on Gait in Patients With Parkinson Disease. American Journal of Physical Medicine and Rehabilitation, 2018, 97, 7-15.	0.7	31
69	Association between Sleep Disturbances and Daytime Somnolence in Parkinson's Disease. European Neurology, 2018, 80, 268-276.	0.6	7
70	Introducing the new "Movement Disorders Rounds― Parkinsonism and Related Disorders, 2018, 55, 1.	1.1	0
71	Exploring Bedroom Usability and Accessibility in Parkinson's Disease (PD): The Utility of a PD Home Safety Questionnaire and Implications for Adaptations. Frontiers in Neurology, 2018, 9, 360.	1.1	5
72	Time for a strategy in night-time dopaminergic therapy? An objective sensor-based analysis of nocturnal hypokinesia and sleeping positions in Parkinson's disease. Journal of the Neurological Sciences, 2017, 373, 244-248.	0.3	21

#	Article	IF	CITATIONS
73	Knowledge, attitudes and perceptions of Parkinson's disease: A cross-sectional survey of Asian patients. Journal of the Neurological Sciences, 2017, 374, 69-74.	0.3	23
74	The sleeping brain in Parkinson's disease: A focus on REM sleep behaviour disorder and related parasomnias for practicing neurologists. Journal of the Neurological Sciences, 2017, 374, 32-37.	0.3	12
75	Editorial and introduction: Behavioral aspects of Parkinson's disease. Journal of the Neurological Sciences, 2017, 374, 1-2.	0.3	1
76	Objective Measurement and Monitoring of Nonmotor Symptoms in Parkinson's Disease. International Review of Neurobiology, 2017, 133, 347-387.	0.9	5
77	Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinson's Disease in Selected Asian Populations. Neuroepidemiology, 2017, 49, 1-17.	1.1	29
78	Tremor's glove-an innovative electrical muscle stimulation therapy for intractable tremor in Parkinson's disease: A randomized sham-controlled trial. Journal of the Neurological Sciences, 2017, 381, 331-340.	0.3	28
79	Systematic review of hardware-related complications of Deep Brain Stimulation: Do new indications pose an increased risk?. Brain Stimulation, 2017, 10, 967-976.	0.7	118
80	Clinical Assessments in Parkinson's Disease. International Review of Neurobiology, 2017, 132, 129-182.	0.9	63
81	Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor. Parkinsonism and Related Disorders, 2017, 44, 124-128.	1.1	29
82	Impaired bed mobility: quantitative torque analysis with axial inertial sensors. Neurodegenerative Disease Management, 2017, 7, 235-243.	1.2	8
83	RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials. Journal of Clinical Movement Disorders, 2017, 4, 9.	2.2	19
84	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology, 2017, 264, 112-120.	1.8	32
85	Ixcellence Network�: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. Functional Neurology, 2017, 32, 103.	1.3	7
86	Beyond the Classic Segawa Disease, GCH1-Associated Neurodegenerative Parkinsonism: Practical Considerations for Physicians. Journal of Movement Disorders, 2017, 10, 102-104.	0.7	6
87	Myoclonus and Startle Syndromes. , 2017, , 315-325.		0
88	Axial Sensory Tricks in Chorea-Acanthocytosis: Insights into Phenomenology. Tremor and Other Hyperkinetic Movements, 2017, 7, 475.	1.1	1
89	Physicians' role in the determination of fitness to drive in patients with Parkinson's disease: systematic review of the assessment tools and a call for national guidelines. Journal of Clinical Movement Disorders, 2016, 3, 14.	2.2	9
90	Unmet needs in Parkinson's disease: New horizons in a changing landscape. Parkinsonism and Related Disorders, 2016, 33, S2-S8.	1.1	19

#	Article	IF	CITATIONS
91	Practical management of adverse events related to apomorphine therapy. Parkinsonism and Related Disorders, 2016, 33, S42-S48.	1.1	28
92	Quantitative demonstration of the efficacy of night-time apomorphine infusion to treat nocturnal hypokinesia in Parkinson's disease using wearable sensors. Parkinsonism and Related Disorders, 2016, 33, S36-S41.	1.1	27
93	Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therapy. Parkinsonism and Related Disorders, 2016, 33, S49-S55.	1.1	31
94	What daily activities increase the risk of falling in Parkinson patients? An analysis of the utility of the ABC-16 scale. Journal of the Neurological Sciences, 2016, 364, 183-187.	0.3	19
95	Support vector machine classification of Parkinson's disease and essential tremor subjects based on temporal fluctuation. , 2016, 2016, 6389-6392.		27
96	Biochemical and clinical effects of Whey protein supplementation in Parkinson's disease: A pilot study. Journal of the Neurological Sciences, 2016, 367, 162-170.	0.3	43
97	How well do Parkinson's disease patients turn in bed? Quantitative analysis of nocturnal hypokinesia using multisite wearable inertial sensors. Parkinsonism and Related Disorders, 2016, 23, 10-16.	1.1	46
98	Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. Neurotoxicity Research, 2016, 29, 105-117.	1.3	79
99	Strategies for treatment of dystonia. Journal of Neural Transmission, 2016, 123, 251-258.	1.4	31
100	Sensor-based evaluation and treatment of nocturnal hypokinesia in Parkinson's disease: An evidence-based review. Parkinsonism and Related Disorders, 2016, 22, S127-S133.	1.1	29
101	Capturing nighttime symptoms in Parkinson disease: Technical development and experimental verification of inertial sensors for nocturnal hypokinesia. Journal of Rehabilitation Research and Development, 2016, 53, 487-498.	1.6	25
102	Analysis of SCA8, SCA10, SCA12, SCA17 and SCA19 in patients with unknown spinocerebellar ataxia: a Thai multicentre study. BMC Neurology, 2015, 15, 166.	0.8	19
103	Temporal fluctuations of tremor signals from inertial sensor: a preliminary study in differentiating Parkinson's disease from essential tremor. BioMedical Engineering OnLine, 2015, 14, 101.	1.3	29
104	Effective Delivery of Apomorphine in the Management of Parkinson Disease. Clinical Neuropharmacology, 2015, 38, 89-103.	0.2	48
105	Visual deprivation elicits subclinical postural inflexibilities in early Parkinson's disease. Journal of the Neurological Sciences, 2015, 349, 214-219.	0.3	21
106	Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. Parkinsonism and Related Disorders, 2015, 21, 111-115.	1.1	26
107	Oneiric stupor in a 45-year-old nurse with rapidly progressive dementia: What is the diagnosis?. Clinical Neurology and Neurosurgery, 2015, 137, 102-104.	0.6	1
108	Asian perspectives on the recognition and management of levodopa â€~wearing-off' in Parkinson's disease. Expert Review of Neurotherapeutics, 2015, 15, 1285-1297.	1.4	22

#	Article	IF	CITATIONS
109	Exploring the effect of electrical muscle stimulation as a novel treatment of intractable tremor in Parkinson's disease. Journal of the Neurological Sciences, 2015, 358, 146-152.	0.3	28
110	What is the evidence to support home environmental adaptation in Parkinson's disease? A call for multidisciplinary interventions. Parkinsonism and Related Disorders, 2015, 21, 1127-1132.	1.1	25
111	Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 61-67.	1.1	32
112	Identifying gaps in knowledge about Parkinson disease among medical professionals in Thailand. Neurology, 2014, 82, 2238-2240.	1.5	24
113	Transplacental transfer of NMDA receptor antibodies in an infant with cortical dysplasia. Neurology, 2014, 82, 1662-1663.	1.5	33
114	Nocturnal manifestations of Parkinson's disease and atypical Parkinsonism. Journal of Neural Transmission, 2014, 121, 1-2.	1.4	1
115	Nocturnal manifestations of atypical and vascular parkinsonism: How do they differ from Parkinson's disease?. Journal of Neural Transmission, 2014, 121, 69-77.	1.4	5
116	Nocturnal journey of body and mind in Parkinson's disease: the manifestations, risk factors and their relationship to daytime symptoms. Evidence from the NIGHT-PD study. Journal of Neural Transmission, 2014, 121, 59-68.	1.4	57
117	The impact of the nocturnal disabilities of Parkinson's disease on caregivers' burden: implications for interventions. Journal of Neural Transmission, 2014, 121, 15-24.	1.4	47
118	Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy. Clinical Neurology and Neurosurgery, 2014, 116, 1-3.	0.6	2
119	Nocturnal Manifestations of Atypical Parkinsonian Disorders. Journal of Parkinson's Disease, 2014, 4, 223-236.	1.5	8
120	Low-Cost, 3-Dimension, Office-Based Inertial Sensors for Automated Tremor Assessment: Technical Development and Experimental Verification. Journal of Parkinson's Disease, 2014, 4, 273-282.	1.5	16
121	The Arizona Sexual Experiences Scale: A Validity and Reliability Assessment of the Thai Translation (ASEX-Thai) in Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 205-210.	1.5	10
122	Evidence-based guideline: Treatment of tardive syndromes. Neurology, 2013, 81, 463-469.	1.5	189
123	Tremor assessment using spiral analysis in time-frequency domain. , 2013, , .		7
124	Different diagnostic criteria for Parkinson disease: what are the pitfalls?. Journal of Neural Transmission, 2013, 120, 619-625.	1.4	16
125	The spectrum of preclinical gait disorders in early Parkinson's disease: subclinical gait abnormalities and compensatory mechanisms revealed with dual tasking. Journal of Neural Transmission, 2013, 120, 1665-1672.	1.4	29
126	A newly identified locus for benign adult familial myoclonic epilepsy on chromosome 3q26.32-3q28. European Journal of Human Genetics, 2013, 21, 225-228.	1.4	55

#	Article	IF	CITATIONS
127	Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2013, 81, 1967-1967.	1.5	0
128	Recurrent pancreatitis as a rare complication of duodenal levodopa infusion treatment. Movement Disorders, 2013, 28, 1308-1310.	2.2	1
129	Positional Vomiting as the Initial Manifestation of Bruns Syndrome due to Cysticercosis in the Fourth Ventricle: A Symptom Reminiscent of an Old Disease. European Neurology, 2012, 67, 184-185.	0.6	6
130	Parkinson's Disease: Levodopa-Induced Dyskinesia. Current Clinical Neurology, 2012, , 10-11.	0.1	0
131	Therapeutic strategies for nonmotor symptoms in early Parkinson's disease: the case for a higher priority and stronger evidence. Parkinsonism and Related Disorders, 2012, 18, S110-S113.	1.1	22
132	Expanding spectrum of abnormal movements in MELAS syndrome (mitochondrial encephalomyopathy,) Tj ETQq0	0.0.rgBT 2:2	Overlock 10
133	Boxing and Parkinson disease: A link or a myth? An 18F-FDOPA PET/CT study in retired Thai traditional boxers. Parkinsonism and Related Disorders, 2012, 18, 694-696.	1.1	11
134	The first case report of neuroacanthocytosis in Thailand: Utilization of a proper technique searching for acanthocytes. Clinical Neurology and Neurosurgery, 2012, 114, 425-426.	0.6	1
135	A low-cost intervention for improving gait in Parknson's disease patients: A cane providing visual cues. European Geriatric Medicine, 2012, 3, 126-130.	1.2	16
136	Prevalence of neuroleptic-induced restless legs syndrome in patients taking neuroleptic drugs. Journal of the Neurological Sciences, 2012, 314, 158-160.	0.3	21

137	Movement disorders in patients with diabetes mellitus. Journal of the Neurological Sciences, 2012, 314, 5-11.	0.3	32
138	Opsoclonus-Myoclonus-Ataxia Syndrome. Current Clinical Neurology, 2012, , 196-197.	0.1	0

139	Addiction-Like Manifestations and Parkinson's Disease: A Large Single Center 9-Year Experience. International Journal of Neuroscience, 2012, 122, 145-153.	0.8	37
140	Tardive Dystonia. Current Clinical Neurology, 2012, , 126-127.	0.1	0
141	Examination of a Patient with Non-DYT1 Generalized Dystonia. Current Clinical Neurology, 2012, , 78-79.	0.1	0
142	Chorea-Acanthocytosis with Feeding Dystonia. Current Clinical Neurology, 2012, , 156-157.	0.1	0
143	Multiple System Atrophy. Current Clinical Neurology, 2012, , 30-31.	0.1	0

144 DYT1 Generalized Dystonia. Current Clinical Neurology, 2012, , 80-81.

0.1 0

#	Article	IF	CITATIONS
145	Friedreich's Ataxia. Current Clinical Neurology, 2012, , 228-229.	0.1	Ο
146	Medical therapy for dystonia. , 2012, , 357-373.		0
147	Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. Functional Neurology, 2012, 27, 225-30.	1.3	14
148	Startle syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 421-430.	1.0	13
149	Spectrum of tardive syndromes: clinical recognition and management. Postgraduate Medical Journal, 2011, 87, 132-141.	0.9	77
150	A census of movement disorders at a Thai university hospital. Journal of the Neurological Sciences, 2011, 301, 31-34.	0.3	19
151	Introduction. Parkinsonism and Related Disorders, 2011, 17, S1-S2.	1.1	Ο
152	Prevalence and diagnostic challenge of dystonia in Thailand: A service-based study in a tertiary university referral centre. Parkinsonism and Related Disorders, 2011, 17, S15-S19.	1.1	12
153	Treatment of complex cervical dystonia with botulinum toxin: Involvement of deep-cervical muscles may contribute to suboptimal responses. Parkinsonism and Related Disorders, 2011, 17, S20-S24.	1.1	21
154	Mixed results for GPi-DBS in the treatment of cranio-facial and cranio-cervical dystonia symptoms. Journal of Neurology, 2011, 258, 2069-2074.	1.8	43
155	10 Commonly Asked Questions About Parkinson Disease. Neurologist, 2011, 17, 57-62.	0.4	0
156	Reduced Serum Caeruloplasmin Levels in Non-Wilsonian Movement Disorders. European Neurology, 2011, 66, 123-127.	0.6	10
157	A National Registry to Determine the Distribution and Prevalence of Parkinson's Disease in Thailand: Implications of Urbanization and Pesticides as Risk Factors for Parkinson's Disease. Neuroepidemiology, 2011, 37, 222-230.	1.1	32
158	Prevalence and risk factors of Parkinson's disease in retired Thai traditional boxers. Movement Disorders, 2010, 25, 1895-1901.	2.2	33
159	Lingual myoclonus secondary to bilateral cortical strokes in a probable case of antiphospholipid syndrome. Movement Disorders, 2010, 25, 2000-2002.	2.2	5
160	HIV-related opsoclonus–myoclonus–ataxia syndrome: Report on two cases. Clinical Neurology and Neurosurgery, 2010, 112, 572-574.	0.6	33
161	The first case report of neuroacanthocytosis in Thailand: Utilization of a peripheral blood smear technique for detecting acanthocytes. Clinical Neurology and Neurosurgery, 2010, 112, 541-543.	0.6	6
162	Juvenile parkinsonism. European Journal of Paediatric Neurology, 2009, 13, 290-292.	0.7	1

#	Article	IF	CITATIONS
163	Reversible Parkinsonism after chronic cyclosporin treatment in renal transplantation. Movement Disorders, 2009, 24, 1848-1849.	2.2	8
164	Complex movement disorders in a sporadic Boucherâ€NeuhÃ ¤ ser Syndrome: Phenotypic manifestations beyond the triad. Movement Disorders, 2009, 24, 2304-2306.	2.2	9
165	Treatment of Parkinson's disease in Thailand: review of the literature and practical recommendations. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2009, 92, 142-54.	0.4	0
166	Evidence for effectiveness of botulinum toxin for hyperhidrosis. Journal of Neural Transmission, 2008, 115, 641-645.	1.4	27
167	Evidence for the effectiveness of botulinum toxin for sialorrhoea. Journal of Neural Transmission, 2008, 115, 631-635.	1.4	18
168	Management of non-motor symptoms in advanced Parkinson disease. Journal of the Neurological Sciences, 2008, 266, 216-228.	0.3	97
169	Motor complications in Parkinson disease: Clinical manifestations and management. Journal of the Neurological Sciences, 2008, 266, 204-215.	0.3	48
170	Reply from the authors: Motor complications in Parkinson disease: Clinical manifestations and management. Journal of the Neurological Sciences, 2008, 273, 156-157.	0.3	0
171	Multiple System Atrophy. Neurologist, 2008, 14, 224-237.	0.4	25
172	Post-hypoxic animal model of myoclonus. Parkinsonism and Related Disorders, 2007, 13, 377-381.	1.1	21
173	"Dystonic―body perception in childhood dystonia. Clinical Neurology and Neurosurgery, 2007, 109, 446-447.	0.6	6
174	Myoclonus and parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 549-560.	1.0	5
175	Medical image. "Hot cross bun" sign. New Zealand Medical Journal, 2007, 120, U2563.	0.5	0
176	Atypical dementia: when it is not Alzheimer's disease. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2007, 90, 2222-32.	0.4	2
177	Treatment of dystonia. Expert Review of Neurotherapeutics, 2006, 6, 863-886.	1.4	33
178	Dystonia. Neurologist, 2006, 12, 74-85.	0.4	43
179	How useful is (1231) beta-CIT SPECT in the diagnosis of Parkinson's disease?. Reviews in Neurological Diseases, 2006, 3, 19-22.	0.3	6
180	Bilateral neurostimulation systems used for deep brain stimulation: in vitro study of MRI-related heating at 1.5 T and implications for clinical imaging of the brain. Magnetic Resonance Imaging, 2005, 23, 549-555.	1.0	49

#	Article	IF	CITATIONS
181	Favorable longitudinal outcome in a patient with Parry-Romberg syndrome. Acta Neurologica Scandinavica, 2005, 112, 192-193.	1.0	8
182	Dystonia (DYT) genetic loci. European Journal of Paediatric Neurology, 2005, 9, 367-370.	0.7	7
183	Three brothers with a very-late-onset writer's cramp. Movement Disorders, 2005, 20, 1375-1377.	2.2	16
184	Postmortem analysis of pallidotomy in Parkinson?s disease. Journal of Neurology, 2005, 252, 100-102.	1.8	2
185	Late-Onset Friedreich Ataxia. Archives of Neurology, 2005, 62, 1865.	4.9	111
186	Midbrain Ataxia: An Introduction to the Mesencephalic Locomotor Region and the Pedunculopontine Nucleus. American Journal of Roentgenology, 2005, 184, 953-956.	1.0	51
187	Differential diagnosis of common tremor syndromes. Postgraduate Medical Journal, 2005, 81, 756-762.	0.9	132
188	Improvement of cervical dystonia: possible role of transcranial magnetic stimulation simulating sensory tricks effect. Medical Hypotheses, 2005, 64, 941-945.	0.8	18
189	Expanding use of botulinum toxin. Journal of the Neurological Sciences, 2005, 235, 1-9.	0.3	138
190	Tourette's syndrome: old syndrome, new insights and new treatment. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88, 1462-70.	0.4	0
191	Tourette's syndrome: old syndrome, new insights and new treatment. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88 Suppl 4, S339-47.	0.4	2
192	Chorea and related disorders. Postgraduate Medical Journal, 2004, 80, 527-534.	0.9	88
193	Subdural Hematoma and Retinal Hemorrhages in an Infant: Accidental or Nonaccidental Injury?. Pediatric Neurosurgery, 2004, 40, 147-148.	0.4	1
194	Wound botulism. Postgraduate Medical Journal, 2004, 80, 240-240.	0.9	2
195	Cerebellar arteriovenous malformation presenting with bilateral proptosis mimicking caroticocavernous fistula. British Journal of Hospital Medicine, 2004, 65, 690-691.	0.3	0
196	Midbrain Ataxia: Possible Role of the Pedunculopontine Nucleus in Human Locomotion. Cerebrovascular Diseases, 2003, 16, 95-96.	0.8	24
197	Segmental Unilateral Lentiginosis in Generalized Neurofibromatosis Type 1. Archives of Neurology, 2002, 59, 1331.	4.9	6
198	Saccadic and Vestibular Abnormalities in Multiple Sclerosis. Annals of the New York Academy of Sciences, 2002, 956, 438-440.	1.8	43

#	Article	IF	CITATIONS
199	Ocular oscillations induced by shifts of the direction and depth of visual fixation. Annals of Neurology, 2001, 49, 24-28.	2.8	16
200	Correction of mesalazine-induced neutropenia with high dose G-CSF. American Journal of Gastroenterology, 2000, 95, 3321-3322.	0.2	7
201	A hypothetical scheme for the brainstem control of vertical gaze. Neurology, 2000, 54, 1985-1993.	1.5	150
202	Botulinum neurotoxin in oromandibular dystonia. , 0, , 64-70.		0
203	Subdural Empyema. , 0, , 245-247.		0
204	Appendix: Treatment Algorithm for Parkinson's Disease. , 0, , 681-682.		0
205	Disorders of Amino Acid, Organic Acid, and Ammonia Metabolism. , 0, , 609-616.		0
206	Introduction to Protozoans of the Central Nervous System. , 0, , 278-278.		0
207	Movement Disorders: An Overview. , 0, , 144-145.		0
208	Scapuloperoneal Syndrome. , 0, , 225-226.		0
209	Floppy Infant Syndrome. , 0, , 596-599.		0
210	Sleep Abnormalities in Neurological Disorders. , 0, , 577-578.		0
211	HIV and the Acquired Immunodeficiency Syndrome: An Overview of Neurological Complications. , 0, , 340-341.		0
212	Stroke: An Overview. , 0, , 1-1.		1
213	Rickettsial and Parasitic Infections. , 0, , 293-293.		0
214	Facial and Neck Pain. , 0, , 675-678.		0
215	Mycobacterium Avium. , 0, , 261-261.		0
216	Genetics in Neurology. , 0, , 480-484.		0